Contour changes after guided bone regeneration of large non-contained mandibular buccal bone defects using deproteinized bovine bone mineral and a porcine-derived collagen membrane: an experimental in vivo investigation
Sign Up to like & getrecommendations! Published in 2017 at "Clinical Oral Investigations"
DOI: 10.1007/s00784-017-2214-z
Abstract: ObjectiveThe objective of this study was to evaluate soft tissue contour changes after three different regenerative therapies in chronic ridge defects.Material and methodsBuccal bone defects were created in the mandible of nine beagle dogs. Augmentation… read more here.
Keywords: brg; collagen; bone; contour changes ... See more keywords
Negative correlations between bile reflux gastritis and Helicobacter pylori infection
Sign Up to like & getrecommendations! Published in 2022 at "Scandinavian Journal of Gastroenterology"
DOI: 10.1080/00365521.2022.2094721
Abstract: Abstract Objective There are a few articles to study the relationship between bile reflux gastritis (BRG) and H. pylori infection, and the results are debatable. This study set out to determine the relationship between BRG… read more here.
Keywords: brg; relationship; pylori infection; infection ... See more keywords
Activity of brigatinib (BRG) in crizotinib (CRZ)-resistant ALK+ NSCLC patients (pts) according to ALK plasma mutation status.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.9065
Abstract: 9065Background: BRG is a potent and selective ALK inhibitor with preclinical and clinical activity against wild-type ALK and a broad range of mutants associated with clinical CRZ resistance, including G1202R. Herein we examine the association… read more here.
Keywords: brg; resistant alk; alk; alk nsclc ... See more keywords
Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.e20503
Abstract: e20503Background: Most ALK+ NSCLC patients (pts) receiving CRZ eventually experience disease progression. Based on promising activity in a phase 1/2 trial, a randomized phase 2 trial of the ALK inhibitor BRG in pts with CRZ-refractory,… read more here.
Keywords: brg; alk; crz refractory; randomized phase ... See more keywords